(VIR) – Company Press Releases
-
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
-
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
-
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
-
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
-
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
-
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
-
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
-
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
-
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation
-
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
-
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
-
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
-
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
-
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
-
Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer
-
Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
-
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
-
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
-
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
-
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
-
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
-
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
-
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
-
Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023
-
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
-
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
-
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
-
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023
-
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
-
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
-
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
-
Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders
-
Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer
-
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
-
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference
-
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
-
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
-
Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference
-
Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference
-
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results
-
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
-
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
-
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
-
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
-
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
-
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
Back to VIR Stock Lookup
